Treatment of Hypertensive Urgency in AKI

Critical Initial Assessment

The American College of Cardiology recommends confirming hypertensive urgency, not emergency, by verifying BP >180/120 mmHg with repeat measurements in both arms 2
Actively exclude acute target organ damage through systematic evaluation, including a brief neurological exam and fundoscopy, as recommended by the American Heart Association 1, 3
Perform laboratory screening, including CBC, creatinine, LDH, and haptoglobin, to exclude thrombotic microangiopathy, as suggested by the American Society of Nephrology 2

The American College of Cardiology recommends targeting gradual BP lowering over 24-48 hours to safer levels, generally <160/100 mmHg, using oral antihypertensive therapy, such as labetalol or an ACE inhibitor/ARB at very low doses 1, 2, 3
Avoid reducing BP to "normal" levels acutely, as patients with chronic hypertension and diabetic CKD have altered cerebrovascular autoregulation and cannot tolerate acute normalization, as recommended by the American Diabetes Association 1, 2

Labetalol is specifically recommended as first-line for hypertensive urgency, with a starting dose and observation for at least 2 hours after administration, as suggested by the American College of Cardiology 2, 3
ACE inhibitors/ARBs are reasonable in diabetic CKD with albuminuria to slow kidney disease progression, but start at very low doses due to unpredictable responses in the acute setting, as recommended by the American Society of Nephrology 4, 5

Observe for at least 2 hours after oral medication administration to evaluate efficacy and safety, as recommended by the American College of Cardiology 2
Monitor for symptoms of hypotension, such as fatigue and light-headedness, and check basic metabolic profile within 2-4 weeks after medication initiation or dose changes, as suggested by the American Society of Nephrology 4, 5

Close outpatient follow-up within one week is essential, with clinic follow-up every 6-8 weeks until BP goal safely achieved, as recommended by the American College of Cardiology 1, 2
Screen for secondary hypertension causes after stabilization, such as renal artery stenosis, pheochromocytoma, and primary aldosteronism, as suggested by the American Society of Hypertension 1, 3

Do not admit or use IV medications for hypertensive urgency without acute organ damage, as recommended by the American College of Cardiology 1, 2, 3
Do not rapidly lower BP to "normal" in the acute setting, as this can cause ischemic complications in patients with chronic hypertension, as suggested by the American Heart Association 1, 2
Do not combine ACE inhibitor + ARB, due to increased risks of hyperkalemia and AKI, as recommended by the American Society of Nephrology 6